Viral vector vaccine

In addition to the SARS coronavirus-2 that is currently prevalent worldwide, scientists continue to keep an eye on the related MERS coronavirus, as it, too, could potentially become a supra-regional

This year, the German Center for Infection Research (DZIF) is honouring two researchers who have been engaged in virus research for many years and are currently actively working on a vaccine against

As part of the research activities within the German Center for Infection Research (DZIF), scientists of the Paul-Ehrlich-Institut studied specific vaccine candidates against COVID-19. They are based

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, today approved the clinical trial of the MVA-SARS-2-S vaccine against COVID-19. The vector vaccine was developed by

Joint vaccine development under the roof of the DZIF: Vaccine is currently being manufactured for use in clinical trials

A potential vaccine against SARS-CoV-2 is to undergo first clinical trials on

Over the past 20 years, coronaviruses have been responsible for large outbreaks, resulting in severe respiratory illness and a number of deaths. These include the SARS coronavirus outbreak in 2002

Research has been called to develop drugs, vaccines and testing methods as quickly as possible to fight the SARS-coronavirus-2. A fast-track procedure has made additional funding available to

Scientists and physicians at the German Center for Infection Research (DZIF) have been closely monitoring and investigating the development of the novel coronavirus SARS-CoV-2 since it first emerged